Trial Profile
Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Eribulin (Primary)
- Indications Adenocarcinoma; Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Mar 2020 Status changed from recruiting to discontinued.
- 13 Aug 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2021.
- 13 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.